Showing results (591-600 of 671) with videos related to

Sort By:
Pageof 68
Nature Communications|October 29, 2014
Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppressionLimo Chen, Don L Gibbons, Sangeeta Goswami, et al.
Cancer Immunology, Immunotherapy : CII|April 18, 2020
<sup>18</sup>F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancerKyle G Mitchell, Behrang Amini, Yunfei Wang, et al.
American Journal of Respiratory and Critical Care Medicine|July 31, 2020
Augmented Lipocalin-2 Is Associated with Chronic Obstructive Pulmonary Disease and Counteracts Lung Adenocarcinoma DevelopmentWarapen Treekitkarnmongkol, Maya Hassane, Ansam Sinjab, et al.
Cancers|April 3, 2021
Single-Cell Expression Landscape of SARS-CoV-2 Receptor <i>ACE2</i> and Host Proteases in Normal and Malignant Lung Tissues from Pulmonary Adenocarcinoma PatientsGuangchun Han, Ansam Sinjab, Kieko Hara, et al.
Lancet (London, England)|July 21, 2023
Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trialJoe Y Chang, Steven H Lin, Wenli Dong, et al.
JAMA|May 22, 2014
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugsMark G Kris, Bruce E Johnson, Lynne D Berry, et al.
NPJ Precision Oncology|November 18, 2024
Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasmsAlejandra G Serrano, Pedro Rocha, Cibelle Freitas Lima, et al.
The Lancet. Oncology|August 7, 2022
Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trialNeeta Somaiah, Anthony P Conley, Edwin Roger Parra, et al.
Journal for Immunotherapy of Cancer|July 22, 2024
First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumorsMartin Wermke, Tobias A W Holderried, Jason John Luke, et al.
Nature Communications|August 20, 2021
Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancerTina Cascone, Annikka Weissferdt, Myrna C B Godoy, et al.
Pageof 68